prourocare medical inc (PUMD) Key Developments
ProUroCare Medical Files Form 15
Mar 14 14
ProUroCare Medical Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.00001 par value per share under the Securities Exchange Act of 1934, as amended.
ProUroCare Medical Inc. To Delist From The OTCQB And Deregister Its Common Stock, Units And Warrants
Mar 12 14
ProUroCare Medical Inc. announced that it intends to remove its common stock from trading on the OTCQB and to file a Form 15 with the Securities and Exchange Commission ("SEC") on or about March 14, 2014. The Company also announced that because its common stock, warrants and units are held by less than 300 holders of record and were held by less than 300 holders of record as of January 1, 2014, it expects to terminate the registration of its common stock, warrants and units under Section 12(g) and to suspend its reporting obligations under Section 15(d) of the Securities Exchange Act of 1934, as amended by filing the Form 15 with the SEC. The Company is taking this action in order to reduce the legal, accounting and administrative costs associated with being a reporting company under the Exchange Act and to allow the Company to explore options for a refinancing, restructuring or a sale of the Company or its assets without the burdens of its current public reporting status. There is no assurance that any such transaction will be completed. The Company anticipates that the OTCQB will suspend trading in the Company's common stock on the date the Company's Form 15 is filed with the SEC. Accordingly, the last day the Company's common stock will trade on OTCQB is on or about March 14, 2014. Upon filing the Form 15 with the SEC, the obligations of the Company to file certain periodic reports, including Forms 10-K, 10-Q and 8-K, will be suspended on a going forward basis. The Company anticipates that its common stock will commence quotation on the OTC Pink Marketplace after its delisting from the OTCQB to the extent market makers agree to make a market in its stock. No assurance, however, can be given that a trading market in the Company's common stock through the OTC Pink Marketplace will commence or be maintained.
ProUroCare Medical Inc. Announces Resignation of Robert Rudelius from the Board of Directors
Feb 12 14
On February 11, 2014, Robert Rudelius resigned from the board of directors of ProUroCare Medical Inc. and has told the company that he is planning to organize a group of investors to make a significant investment in the company.
ProUroCare Medical Inc. Appoints David Kaysen as a Member of Board of Directors
Sep 10 13
On September 9, 2013, ProUroCare Medical Inc. announced that the company’s Board of Directors had appointed David Kaysen as a member of its Board of Directors, effective September 9, 2013. A decision on Mr. Kaysen’s committee membership is still pending. From May 2006 until April 2013, Mr. Kaysen was President, CEO and a director of Uroplasty Inc.